Mesothelioma study: MRTX1719
Official title Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
ClinicalTrials.gov ID: NCT05245500
What this study is testing
What is MRTX1719?
MRTX1719 is an investigational oral medicine being studied for the treatment of mesothelioma and other solid tumors with a specific genetic deletion. It is designed to inhibit the PRMT5-MTA enzyme pathway.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see how safe and well tolerated MRTX1719 is, and to learn about its blood levels, how it works in the body, and whether it can shrink tumors.
- Who it's for
- It is looking for adults with advanced, unresectable or metastatic solid tumors that have a homozygous deletion of the MTAP gene, such as mesothelioma, non‑small cell lung cancer, pancreatic cancer, or other solid cancers.
- What's involved
- Participants will receive MRTX1719 and have regular clinic visits for safety checks, blood tests, imaging scans, and other tests to monitor the drug’s effects.
- Time commitment
- The study lasts until the participant’s treatment is finished, with visits scheduled throughout the treatment period and follow‑up appointments afterward.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue.
- Unresectable or metastatic disease.
- Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically...
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
You likely can't join if
- Prior treatment with a PRMT5 or MAT2A inhibitor therapy.
- Active brain metastases or carcinomatous meningitis.
- History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.
- Major surgery within 4 weeks of first dose of study treatment.
- History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea...
- Cardiac abnormalities.
See the full eligibility criteria
- Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue.
- Unresectable or metastatic disease.
- Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible.
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ function.
- Prior treatment with a PRMT5 or MAT2A inhibitor therapy.
- Active brain metastases or carcinomatous meningitis.
- History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.
- Major surgery within 4 weeks of first dose of study treatment.
- History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study...
- Cardiac abnormalities.
- Other protocol-defined Inclusion/Exclusion criteria apply.
The study team makes the final eligibility decision.
Where it is enrolling
- Phoenix, Arizona, United States
- Lone Tree, Colorado, United States
- Jacksonville, Florida, United States
- Orlando, Florida, United States
- Brookline, Massachusetts, United States
- Grand Rapids, Michigan, United States
- Norton Shores, Michigan, United States
- Rochester, Minnesota, United States
- New Brunswick, New Jersey, United States
- Mineola, New York, United States
- New York, New York, United States
- Port Jefferson Station, New York, United States
- Chapel Hill, North Carolina, United States
- Nashville, Tennessee, United States
- Dallas, Texas, United States
- Fort Worth, Texas, United States
- Houston, Texas, United States
- San Antonio, Texas, United States
- Tyler, Texas, United States
- Fairfax, Virginia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Phoenix, Arizona, United States; Lone Tree, Colorado, United States; Jacksonville, Florida, United States; Orlando, Florida, United States; Brookline, Massachusetts, United States; Grand Rapids, Michigan, United States and 14 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.